JP2003501385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003501385A5 JP2003501385A5 JP2001501212A JP2001501212A JP2003501385A5 JP 2003501385 A5 JP2003501385 A5 JP 2003501385A5 JP 2001501212 A JP2001501212 A JP 2001501212A JP 2001501212 A JP2001501212 A JP 2001501212A JP 2003501385 A5 JP2003501385 A5 JP 2003501385A5
- Authority
- JP
- Japan
- Prior art keywords
- carnitine
- alkanoyl
- acid
- hmg
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002253 acid Substances 0.000 description 16
- -1 alkanoyl L-carnitine Chemical compound 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 10
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 5
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 5
- 229960002855 simvastatin Drugs 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 3
- 229960003765 fluvastatin Drugs 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- 229960004844 lovastatin Drugs 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 229960002965 pravastatin Drugs 0.000 description 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 2
- QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 description 2
- VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13800899P | 1999-06-08 | 1999-06-08 | |
| US60/138,008 | 1999-06-08 | ||
| EP99830415.8 | 1999-06-30 | ||
| EP99830415A EP1064943B1 (en) | 1999-06-30 | 1999-06-30 | Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs |
| PCT/EP2000/005091 WO2000074675A1 (en) | 1999-06-08 | 2000-06-05 | Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003501385A JP2003501385A (ja) | 2003-01-14 |
| JP2003501385A5 true JP2003501385A5 (enExample) | 2007-07-05 |
Family
ID=26153794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001501212A Pending JP2003501385A (ja) | 1999-06-08 | 2000-06-05 | Ｈｍｇ−ｃｏａレダクターゼ阻害剤とカルニチン類を含む抗高脂血症性組合せ |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JP2003501385A (enExample) |
| KR (1) | KR100725263B1 (enExample) |
| AU (1) | AU782188B2 (enExample) |
| CA (1) | CA2375378C (enExample) |
| CZ (1) | CZ20014218A3 (enExample) |
| HU (1) | HUP0201597A3 (enExample) |
| MX (1) | MXPA01012644A (enExample) |
| PL (1) | PL197899B1 (enExample) |
| SK (1) | SK285900B6 (enExample) |
| WO (1) | WO2000074675A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008104239A1 (en) * | 2007-02-27 | 2008-09-04 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composition useful for the treatment of type 2 diabetes |
| ES2546619T3 (es) * | 2007-03-21 | 2015-09-25 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composición útil para la prevención de la diabetes tipo 2 y sus complicaciones en pacientes pre-diabéticos con resistencia a la insulina |
| KR101686917B1 (ko) * | 2008-02-29 | 2016-12-15 | 바이오랩 세너스 팔마씨우티카 엘티디에이. | 라세탐 및 카르니틴을 포함하는 약학 조성물 및 그의 제조방법 |
| US20120130202A1 (en) * | 2010-11-24 | 2012-05-24 | Fujitsu Limited | Diagnosis and Monitoring of Musculoskeletal Pathologies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0667833B2 (ja) * | 1985-11-28 | 1994-08-31 | 雪印乳業株式会社 | 経腸栄養剤 |
| CA2007983C (en) * | 1989-01-18 | 1996-12-10 | Michael S. Brown | Coenzyme q10 with hmg-coa reductase inhibitors |
| IT1293067B1 (it) * | 1997-07-01 | 1999-02-11 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico |
-
2000
- 2000-06-05 PL PL352106A patent/PL197899B1/pl unknown
- 2000-06-05 MX MXPA01012644A patent/MXPA01012644A/es active IP Right Grant
- 2000-06-05 CA CA002375378A patent/CA2375378C/en not_active Expired - Fee Related
- 2000-06-05 SK SK1715-2001A patent/SK285900B6/sk not_active IP Right Cessation
- 2000-06-05 KR KR1020017015675A patent/KR100725263B1/ko not_active Expired - Fee Related
- 2000-06-05 HU HU0201597A patent/HUP0201597A3/hu unknown
- 2000-06-05 AU AU59697/00A patent/AU782188B2/en not_active Ceased
- 2000-06-05 CZ CZ20014218A patent/CZ20014218A3/cs unknown
- 2000-06-05 JP JP2001501212A patent/JP2003501385A/ja active Pending
- 2000-06-05 WO PCT/EP2000/005091 patent/WO2000074675A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2203674T3 (es) | Composicion que contiene propionil l-carnitina y acido hidroxicitrico o acido pantotenico. | |
| WO2001068096A2 (en) | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders | |
| JP2002521428A5 (enExample) | ||
| MXPA05001004A (es) | Formulacion farmaceutica. | |
| RU2003126184A (ru) | Комбинации активатора (активаторов) рецептора, активируемого пролифератором пероксисом (рапп), и ингибитора (ингибиторов) всасывания стерина и лечение заболеваний сосудов | |
| PT2704734E (pt) | Composição útil para o tratamento de distúrbios do metabolismo de lípidos | |
| JP5529165B2 (ja) | 脂質低下薬を経口腔粘膜投与する処方物（ｆｏｒｍｕｌａｔｉｏｎ） | |
| JP2003501385A5 (enExample) | ||
| JP3616116B2 (ja) | 心臓血管障害の処置のためのａｃｅ阻害剤を配合するｌ−カルニチンまたはアシル−ｌ−カルニチンを含む医薬組成物 | |
| AU726822B2 (en) | Pharmaceutical compositions comprising alkanoyl L-carnitine in combination with a statine for treating pathologies brought about by an altered lipid metabolism | |
| EP1758794A1 (en) | A package for at least two different products to be sold and used together | |
| US6245800B1 (en) | Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine | |
| KR100725263B1 (ko) | ＨＭＧ-ＣｏＡ 리덕타제 억제제 및 카르니틴을 포함하는 항지질혈성 복합제 | |
| JPWO2001085155A1 (ja) | 動脈硬化抑制方法及び組成物 | |
| CA2480275A1 (en) | Statin therapy for enhancing cognitive maintenance | |
| JP2004532866A5 (enExample) | ||
| CA2352485A1 (en) | Use of fumarate salt of l-carnitine or its alkanoyl derivatives in ischaemia | |
| EP0539336A1 (en) | Use of L-carnitine or of acyl L-carnitine for the treatment of idiopathic oligoasthenospermias | |
| EP1064943B1 (en) | Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs | |
| JP2002529408A5 (enExample) | ||
| CA2448242A1 (en) | Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain | |
| WO2004021973A3 (en) | Pravastatin pharmaceutical formulations and methods of their use | |
| ZA200601502B (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and improvement of sleep | |
| WO2018017726A1 (en) | Methods and compositions for alleviating myopathy | |
| HK1035134B (en) | The use of alkyl hydrogen fumarates for preparing a pharmaceutical composition in the form of microtablets |